BioVie Inc. (BIVI)
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States.
$1.52+0.06%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-74.8%
The outlook
BioVie Inc. currently reads as leaning bullish based on strong buy — 1.0 avg of 2 analysts, mixed vs its moving averages, 9% of the way from its 52-week low to high, avg target +246% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 2 analysts
Price trendMixed vs its moving averages
52-week range9% of the way from its 52-week low to high
Price targetAvg target +246% vs current price
Analyst price target
~12-month · 2 analysts$5.26average target+245.7% vs now
Now $1.52
Low $5.00High $5.51
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$11.5M
52-wk high
$6.20
52-wk low
$1.06
50-day avg
$1.68
200-day avg
$1.50
Trailing P/E
—